Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 100,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were purchased at an average price of $1.59 per share, with a total value of $159,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 211,712,405 shares of the company’s stock, valued at approximately $336,622,723.95. This trade represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.58 on Friday. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.75. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.08 billion, a PE ratio of -8.32 and a beta of 1.65. The firm has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.44.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OPK shares. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in OPK. CIBC Asset Management Inc raised its position in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 8,978 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of OPKO Health during the first quarter worth approximately $26,000. FMR LLC increased its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Algert Global LLC acquired a new stake in shares of OPKO Health during the second quarter worth approximately $44,000. Finally, Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the third quarter worth approximately $45,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.